Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction.
OBJECTIVE
The aim of our study was to evaluate the safety and midterm clinical results of dexamethasone-eluting stent (DexES) implantation in ST-segment elevation acute myocardial infarction (STEMI).


BACKGROUND
Inflammation plays a pivotal role in both inestabilization of coronary atherosclerotic plaques and development of restenosis after stent placement. Antiinflammatory agents may attenuate those mechanisms and improve clinical outcomes. There is little information about clinical results of DexES and no data are available about their utilization during percutaneous coronary intervention (PCI) in STEMI.


METHODS
Consecutive patients with STEMI that underwent primary or rescue PCI in our institution were treated with DexES. Clinical follow-up with routine realization of noninvasive test for detection of myocardial ischemia and coronariography if necessary, were performed. The objective of the study was to evaluate the rate of MACE (death, reinfarction, or target lesion revascularization) during midterm follow-up.


RESULTS
The procedure was successful in 96.7% of cases. There were no in-hospital deaths or reinfarctions. One acute stent thrombosis occurred and no subacute thrombosis were observed. During a mean follow-up period of 384 days, cardiac-related death was 1.1%, there were no reinfarctions or late stent thrombosis and target lesion revascularization rate was 4.2%.


CONCLUSIONS
We conclude that utilization of DexES for PCI in STEMI is safe and provides good midterm clinical outcomes.
Jimenez-Valero
Santiago
S
Cardiology Department, Hospital Virgen de la Salud, Toledo, Spain.
Santos
Belen
B
Pajin
Fernando
F
Canton
Tomas
T
Lazaro
Esther
E
Moreu
Jose
J
Hernandez
Gonzalo
G
Padial
Luis Rodriguez
LR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D054855:Drug-Eluting Stents; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D055502:Secondary Prevention; D013318:Stroke Volume; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left; D017725:Ventricular Pressure
D000893:Anti-Inflammatory Agents; D002317:Cardiovascular Agents; D003907:Dexamethasone